Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04817826
Title TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST